Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab followed by chemotherapy in recurrent ovarian cancer with ascites
2011-004585-15Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Sep 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of catumaxomab, topotecan, paclitaxel, doxorubicin and gemcitabine in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Feasibility of sequential catumaxomab and chemotherapy. Started Sep 2012; status: terminated.
02
Drugs
catumaxomabtopotecanpaclitaxeldoxorubicingemcitabine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2011-004585-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004585-15.